The Short Bowel Syndrome Market was characterized by intense competition and significant research and development activities. Key pharmaceutical companies and biotech firms were striving to gain a competitive edge in this niche market segment. Some of the prominent players in the SBS market included Shire (a Takeda company), Zealand Pharma, OxThera, and Emmaus Life Sciences.

These companies were actively engaged in Short Bowel Syndrome Market for developing novel therapies and treatment approaches, such as new formulations of parenteral nutrition, growth factors, and intestinal rehabilitation programs. Moreover, ongoing clinical trials and collaborations with healthcare providers and patient organizations were vital components of their strategies to enhance product pipelines and market reach.